Stable non-transforming minimal residual disease in Philadelphia chromosome positive acute lymphoblastic leukemia after autologous transplantation: origin from neoplastic yet ‘pre-leukemic’ stem cells?

References

• Radich JP. Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol Oncol Clin North Am 2001;15:21–36.
   PubMed Web of Science ®Google Scholar
• Harrison CJ, Foroni L. Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Rev Clin Exp Hematol 2002;6:91–113.
   PubMedGoogle Scholar
• Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 1998;91:3995–4019.
   PubMed Web of Science ®Google Scholar
• Wetzler M, Dodge RK, Mrózek K, , Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood 1999;93:3983–3993.
   PubMed Web of Science ®Google Scholar
• Faderl S, Kantarjian HM, Thomas DA, Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma 2000;36:263–273.
   PubMed Web of Science ®Google Scholar
• Gleissner B, Gökbuget N, Bartram CR, Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002;99:1536–1543.
   PubMed Web of Science ®Google Scholar
• Dombret H, Gabert J, Boiron JM, Groupe d'Etude et de Traitement de la Leucémie Aiguë Lymphoblastique de l'Adulte (GET-LALA Group). Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia–results of the prospective multicenter LALA-94 trial. Blood 2002;100:2357–2366.
   PubMed Web of Science ®Google Scholar
• Hoelzer D. Advances in the management of Ph-positive ALL. Clin Adv Hematol Oncol 2006;4:804–805.
   PubMedGoogle Scholar
• Druker BJ, Sawyers CL, Kantarjian H, Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038–1042.
   PubMed Web of Science ®Google Scholar
• Alvarado Y, Apostolidou E, Swords R, Giles FJ. Emerging therapeutic options for Philadelphia-positive acute lymphocytic leukemia. Expert Opin Emerg Drugs 2007;12:165–179.
   PubMed Web of Science ®Google Scholar
• Towatari M, Yanada M, Usui N, Japan Adult Leukemia Study Group. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 2004;104:3507–3512.
   PubMed Web of Science ®Google Scholar
• Wassmann B, Gökbuget N, Scheuring UJ, GMALL Study Group. A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10). Ann Hematol 2003;82:716–720.
   PubMed Web of Science ®Google Scholar
• Kiehl MG, Kraut L, Schwerdtfeger R, Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol 2004;22:2816–2825.
   PubMed Web of Science ®Google Scholar
• Thomas X, Boiron JM, Huguet F, Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004;22:4075–4086.
   PubMed Web of Science ®Google Scholar
• Hallböök H, Hägglund H, Stockelberg D, Swedish Adult ALL Group. Autologous and allogeneic stem cell transplantation in adult ALL: the Swedish Adult ALL Group experience. Bone Marrow Transplant 2005;35:1141–1148.
   PubMed Web of Science ®Google Scholar
• Dhédin N, Dombret H, Thomas X, Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials. Leukemia 2006;20:336–344.
   PubMed Web of Science ®Google Scholar
• Bishop MR, Logan BR, Gandham S, Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research. Bone Marrow Transplant 2008;41:635–642.
   PubMed Web of Science ®Google Scholar
• Cornelissen JJ, van der Holt B, Verhoef GE, Dutch-Belgian HOVON Cooperative Group. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. Blood 2009;113:1375–1382.
   PubMed Web of Science ®Google Scholar
• Doubek M, Folber F, Koristek Z, Autologous hematopoietic stem cell transplantation in adult acute lymphoblastic leukemia: still not out of fashion. Ann Hematol 2009;88:881–887.
   PubMed Web of Science ®Google Scholar
• Radich J, Gehly G, Lee A, Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood 1997;89:2602–2609.
   PubMed Web of Science ®Google Scholar
• Preudhomme C, Henic N, Cazin B, Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL). Leukemia 1997;11:294–298.
   PubMed Web of Science ®Google Scholar
• Mitterbauer G, Nemeth P, Wacha S, Quantification of minimal residual disease in patients with BCR-ABL-positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction. Br J Haematol 1999;106:634–643.
   PubMed Web of Science ®Google Scholar
• Wassmann B, Pfeifer H, Stadler M, Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2005;106:458–463.
   PubMed Web of Science ®Google Scholar
• Giebel S, Stella-Holowiecka B, Krawczyk-Kulis M, Study Group for Adult ALL of the European Leukemia Net. Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL. Bone Marrow Transplant 2010;45:1095–1101.
   PubMed Web of Science ®Google Scholar
• Yanada M, Sugiura I, Takeuchi J, Japan Adult Leukemia Study Group. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy. Br J Haematol 2008;143:503–510.
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Thiel E, Löffler H, Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults. Blood 1984;64:38–47.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kreutzmann H, Straif K, High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia. Blood 1987;69:744–749.
   PubMed Web of Science ®Google Scholar
• Maurer J, Janssen JW, Thiel E, Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction. Lancet 1991;337:1055–1058.
   PubMed Web of Science ®Google Scholar
• Mitterbauer G, Födinger M, Scherrer R, PCR-monitoring of minimal residual leukaemia after conventional chemotherapy and bone marrow transplantation in BCR-ABL-positive acute lymphoblastic leukaemia. Br J Haematol 1995;89:937–941.
   PubMed Web of Science ®Google Scholar
• Chien JH, Tang JL, Chen RL, Li CC, Lee CP. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy. Leuk Res 2008;32:1724–1734.
   PubMed Web of Science ®Google Scholar
• Biernaux C, Loos M, Sels A, Huez G, Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995;86:3118–3122.
   PubMed Web of Science ®Google Scholar
• Colls BM. Monoclonal gammopathy of undetermined significance (MGUS)- 31 year follow up of a community study. Aust NZ J Med 1999;29:500–504.
   PubMedGoogle Scholar
• Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ 3rd. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc 2004;79:859–866.
   PubMed Web of Science ®Google Scholar
• Schaar CG, le Cessie S, Snijder S, Long-term follow-up of a population based cohort with monoclonal proteinaemia. Br J Haematol 2009;144:176–184.
   PubMed Web of Science ®Google Scholar
• Limpens J, Stad R, Vos C, Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood 1995;85:2528–2536.
   PubMed Web of Science ®Google Scholar
• Schüler F, Hirt C, Dölken G. Chromosomal translocation t(14;18) in healthy individuals. Semin Cancer Biol 2003;13:203–209.
   PubMed Web of Science ®Google Scholar
• Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998;92:3362–3367.
   PubMed Web of Science ®Google Scholar
• Valent P. Targeting leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept. Curr Cancer Drug Targets. 2010 Nov 10. [Epub ahead of print].
   Web of Science ®Google Scholar
• Kolb HJ, Schattenberg A, Goldman JM, Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995;86:2041–2050.
   PubMed Web of Science ®Google Scholar
• Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008;112:4371–4383.
   PubMed Web of Science ®Google Scholar
• Molldrem JJ, Lee PP, Kant S, Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest 2003;111:639–647.
   PubMed Web of Science ®Google Scholar
• Grammatico S, Elia L, Peluso AL, Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to imatinib mesylate in BCR-ABL positive acute lymphoblastic leukemia. Leuk Res 2009;33:e73–e74.
   Google Scholar
• Pfeifer H, Wassmann B, Pavlova A, Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2007;110:727–734.
   PubMed Web of Science ®Google Scholar
• Jones D, Thomas D, Yin CC, Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer 2008;113:985–994.
   PubMed Web of Science ®Google Scholar
• Familiades J, Bousquet M, Lafage-Pochitaloff M, PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study. Leukemia 2009;23:1989–1998.
   PubMed Web of Science ®Google Scholar
• Staal FJ, van der Burg M, Wessels LF, DNA microarrays for comparison of gene expression profiles between diagnosis and relapse in precursor-B acute lymphoblastic leukemia: choice of technique and purification influence the identification of potential diagnostic markers. Leukemia 2003;17:1324–1332.
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Miller CB, Radtke I, BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008;453:110–114.
   PubMed Web of Science ®Google Scholar